136 results about "Nicotinamide riboside" patented technology

Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.

The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD⁺ glycohydrolase activity.

Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing nicotinamide riboside. In further embodiments, the invention relates to methods of using nicotinamide riboside to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival. A method of treating signs or symptoms of aging or skin wrinkles in an individual is provided, comprising topically administering to the individual in need of such treatment an effective amount of the compound nicotinamide riboside, or salts thereof.

Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.

Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, for increasing insulin sensitivity in a subject, or to treat or prevent a skin condition. The compounds have general formulas (I) or (II) wherein R1 is -C(=O)-X-(C2-C18 straight chain or branched) alkyl or -C(=O)-X-(C2-C18 straight chain or branched) alkenyl; each R2 is independently selected from hydrogen, and a -C(O)-X-(C2-C18 straight chain or branched) alkyl or a -C(O)-X-(C2-C18 straight chain or branched) alkenyl; and X is a covalent bond or O.

Compositions for addressing one or more of the effects of aging are described. The compositions comprise a first component comprising repair system activator(s) such as nicotinamide adenine dinucleotide (NAD+), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid riboside (NAR), 1-methylnicotinamide (MNM), cyclic adenosine monophosphate (cAMP) and combinations thereof; a second component comprising methyl donor(s), such as S-5'-adenosyl-L-methionine (SAM), methionine, betaine, choline, folate, vitamin B12, or combinations thereof; and a third component comprising antioxidant defense activators, such as H2O2, N2S, NaSH, Na2S, and several others, including combinations thereof.Methods of administering the disclosed compositions or separate formulations of repair system activator, methyl donors, and antioxidant defense activators are also disclosed.

A method of making nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof is disclosed. The method involves contacting at least the following materials to form a solution: i) α-D-ribose-1-phosphate, α-D-ribose-1-phosphate derivatives, or mixtures thereof; ii) nicotinamide, nicotinamide derivatives, or mixtures thereof; iii) one or more pentosyl transferases (E.C. 2.4.2); iv) and one or more solvents. The resulting solution comprises nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof and one or more inorganic orthophosphate anions. The inorganic orthophosphate anions are removed from the solution, leaving a solution of nicotinamide riboside, nicotinamide riboside derivatives, or mixtures thereof.

The disclosure provides derivatives of both the oxidized form and the reduced form of nicotinamide riboside (NR) and nicotinic acid riboside (NAR). The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR, and can increase cellular NAD⁺ levels and improve mitochondrial function. Therefore, the NR and NAR derivatives are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, and other disorders and conditions.

The invention relates to methods of preparing nicotinamide riboside and derivatives thereof. In an aspect, the invention relates to a method of preparing a compound of formula (I), wherein n is 0 or 1; m is 0 or 1; Y is O or S; R₁ is selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted primary or secondary amino, and substituted or unsubstituted azido; R₂-R₅, which may be the same or different, are each independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, and substituted or unsubstituted aryl; and X⁻ is an anion, selected from an anion of a substituted or unsubstituted carboxylic acid, a halide, a substituted or unsubstituted sulfonate, a substituted or unsubstituted phosphate, a substituted or unsubstituted sulfate, a substituted or unsubstituted carbonate, and a substituted or unsubstituted carbamate.

The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD⁺ levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

The invention belongs to the field of chemical synthesis, and particularly relates to a preparation method of beta-nicotinamide ribose chloride (NRC). The technical problem of low-cost high-efficiencysynthesis of the beta-NRC for industrial tonnage production is solved. The preparation method includes the main steps that tetraacetylribose is chlorinated, then condensed with nicotinamide, then a deacetylation reaction is carried out, and the beta-NRC is obtained. The preparation method has the advantages of simple operation, easy amplified production, low cost, good finished product quality and the like.

The invention discloses a combination process of nicotinamide riboside and its derivative with pyrroloquinoline quinone and its sodium salt. The combination process includes: combining any two or three of or all of NR (nicotinamide riboside) (a chloride, or nicotinamide riboside), NMN (beta-nicotinamide mononucleotide), NADH (nicotinamide adenine dinucleotide) and PQQ (pyrroloquinoline quinone disodium salt) into a formulation for making foods, health foods, cosmetics or drugs; the formulation is injected into the human body in external application, oral application or injection manner to takeeffect. The nicotinamide riboside and its derivative function to defy age; the pyrroloquinoline quinone and its sodium salt have the like function and are functionally complementary to nicotinamide riboside; the nicotinamide riboside or its derivative is combined with pyrroloquinoline quinone or its sodium salt into a formulation for making products, such as food additives, health foods, cosmetics and drugs, thereby delaying human senility, maintaining beauty or treating diseases.

Cosmetic methods of increasing ARE activated gene transcription in a skin cell by contacting skin cells in a target portion of skin with an effective amount of niacinamide and nicotinamide riboside in combination to increase ARE activated gene transcription or synergistically increase ARE activated gene transcription of at least some of the skin cells contacted with the niacinamide and nicotinamide riboside. The cosmetic methods also enable synergistic reduction of ROS-induced adenosine triphosphate (ATP) depletion in a skin cell and restoration of glycolytic ATP production rate in a skin cell that has been reduced as a result of ROS-induced oxidative stress.

The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I):

The invention relates to the technical field of NMN preparation and discloses a preparation process of high-purity NMN based on an enzymatic method. The preparation process comprises the following steps: (1) raw material pretreatment: performing microfiltration and nanofiltration on nicotinamide ribose at first, and collecting concentrated crude product solution; (2) a production process: enablingthe crude product solution to react under the catalysis of nicotinamide ribokinase or recombinant cells containing the nicotinamide ribokinase to generate beta-nicotinamide mononucleotide; and (3) apurification process: adjusting the pH value of the produced beta-nicotinamide mononucleotide solution to 3-7, sampling the beta-nicotinamide mononucleotide solution on a reversed-phase high-performance liquid chromatography preparation column, and carrying out gradient elution and purification to obtain the purified beta-nicotinamide mononucleotide solution. The preparation process of the high-purity NMN based on the enzyme method ensures the productivity of the nicotinamide mononucleotide, improves the purity of the product, and can make the nicotinamide mononucleotide more obvious in the effect of relieving and improving the injury of ischemic heart and brain tissues. The nicotinamide mononucleotide can better improve oxidation-related degenerative diseases and body dysfunction.

The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.

The invention discloses a synthesis method of beta-nicotinamide mononucleotide, and relates to the technical field of drug synthesis. The synthesis method mainly comprises the following steps of S1, mixing and reacting nicotinamide, hexamethyldisilazane and a catalyst I in a reaction kettle to obtain silanization-protected nicotinamide; S2, adding tetraacetyl ribose, a solvent, a catalyst II and methanol for reaction so as to generate nicotinamide triacetyl riboside; S3, adding methanol and n-propylamine to generate nicotinamide riboside; S4, adding trimethyl phosphate and phosphorus oxychloride to generate beta-nicotinamide mononucleotide; and S5, separating and purifying the beta-nicotinamide mononucleoside acid. According to the invention, a plurality of continuous steps are controlledto be carried out in one reaction container, and the steps of separating and purifying an intermediate are avoided, so that the method has the advantages of high yield and high production efficiency.

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia are provided herein. Such compositions can contain synergizing amounts of leucine and/or one or more leucine metabolites in combination with nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and with at least one or more anti-diabetic agents. Such compositions can contain sub-therapeutic amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites, and/or sub-therapeutic amounts of one or more anti-diabetic agents that can achieve the same therapeutic efficacy as therapeutic amounts of said compositions in diabetes and/or hyperlipidemia medicaments. The composition can also reduce the side effects associated with treatment using anti-diabetic agents and/or nicotinic acid.